Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAFE: Bevacizumab in 2nd-line mCRC
NCT00862342Phase 2Completed
- Sponsor
- Asan Medical Center
- Start
- Jan 2009
- Primary completion
- Dec 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in metastatic colorectal cancer (mCRC), sponsored by Asan Medical Center. Primary endpoint: Progression Free Survival at 6 weeks. Started Jan 2009; status: completed.
02
Drugs
bevacizumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00862342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00862342.